StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Trading Down 0.9 %
Shares of VBI Vaccines stock opened at $0.75 on Friday. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $1.54. The business’s fifty day moving average price is $0.63 and its 200 day moving average price is $0.62.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The firm had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.85 million. On average, research analysts predict that VBI Vaccines will post -1.23 earnings per share for the current fiscal year.
About VBI Vaccines
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Read More
- Five stocks we like better than VBI Vaccines
- CD Calculator: Certificate of Deposit Calculator
- 3 Insider-Buy Stocks to Add to Your Watchlist Now
- What is the Shanghai Stock Exchange Composite Index?
- Commvault Stock: AI Cybersecurity Giant Ready to Double Again
- What is the S&P/TSX Index?
- Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.